Contribution of DOG1 expression to the diagnosis of gastrointestinal stromal tumors

Kara, Taylan; Serinsöz, Ebru; Arpacı, Rabia Bozdoğan; Gubur, Ozlem; Örekici, Gülhan; Ata, Alper; Çolak, Tahsin; Arıcan, Ali

doi:10.1016/j.prp.2013.04.005

Cited by 15 publications

(20 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GISTs are less common in the rectum, esophagus, omentum and mesentery, with an incidence of 5-10% and in regions outside the GI tract with an incidence of <5% (30,31). The most common location in our cases was the small intestine (51.4%) followed by the stomach (29.7%).…”

Section: Discussionmentioning

confidence: 62%

“…The rate of DOG1 positivity was 20-100% in CD117 negative GIST cases in different studies, all of which reported that DOG1 should be added to the immunohistochemical panel in the diagnostic steps independent of the mutation status (2,(6)(7)(8)29,31,38,42). In the present study, positivity with CD117 was provided by applying the immunohistochemical studies on multiple different paraffin blocks in those cases which could be negative for CD117 (focally and weak reaction).…”

Section: Table 5 Correlation Between Dog1 Immunoexpression and Risk mentioning

confidence: 69%

“…32, No. 4,2015 been produced and used in various studies (2)(3)(4)(5)(6)(7)(8)29,31,38). As summarized in the article of Wong et al (15), the difference in positivity rates is thought to stem from the sensitivity features of the clone used.…”

Section: Table 5 Correlation Between Dog1 Immunoexpression and Risk mentioning

confidence: 99%

“…As summarized in Table 6, collective evaluation of the results of the series where CD117 and DOG1 antibodies were studied together (if we ignore the fact that these studies were performed under different laboratory conditions at different centers and by using different antibody clones) in GISTs (2)(3)(4)(6)(7)(8)(29)(30)(31)38) revealed that the CD117 positivity rate was 91% and DOG1 positivity 93% in about three thousand GIST cases. DOG1 specificity was reported to be a little lower than, equal to or greater than CD117 specificity in different studies.…”

Section: Table 5 Correlation Between Dog1 Immunoexpression and Risk mentioning

confidence: 99%

See 3 more Smart Citations

Histopathological Features of Gastrointestinal Stromal Tumors and the Contribution of DOG1 Expression to the Diagnosis

Guler¹,

Özyilmaz²,

Tokuç³

et al. 2015

Balkan Med J

View full text Add to dashboard Cite

Background:Gastrointestinal stromal tumors (GIST) have KIT or platelet-derived growth factor receptor α (PDGFRα) mutations affecting receptor tyrosine kinase activity and do not benefit from classic treatment regimens. Aims: The aim of this study was to review the algorithm that may be followed for the diagnosis and differential diagnosis in GISTs by investigating the histomorphological parameters and expression characteristics of classical immunohistochemical antibodies used in routine tests in addition to DOG1 expression. Study Design: Diagnostic accuracy study. Methods: We reevaluated the histological and immunohistochemical parameters of 37 GISTs. The standard immunohistochemical diagnosis and differential diagnosis panel antibodies (CD117, PDGFRα, CD34, vimentin, desmin, SMA, S-100, and Ki67) were studied on the tumor sections. We also used the popular marker DOG1 antibody with accepted sensitivity for GISTs in recent years and the PDGFRα immune marker for which the benefit in routine practice is discussed. Results: Classification according to progressive disease risk groups of the 37 cases revealed that 54% were in the high risk, 19% in the moderate risk, 16% in the low risk, 8% in the very low risk and 8% in the no risk group. Cytological atypia, necrosis, mucosal invasion and the Ki67 index were found to be related to the progressive disease risk groups of the tumors (p<0.05). Positive immunoreaction was observed with CD117 and PDGFRα in all GISTs in the study (100%). Positivity with the DOG1 antibody was found in 33 (89%) cases. CD34 was positive in 62% (23) of the cases. Conclusion: The CD117 antibody still plays a key role in GIST diagnosis. However, the use of DOG1 and PDGFRα antibodies combined with CD117 as sensitive markers can be beneficial.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Table 5 Correlation Between Dog1 Immunoexpression and Risk mentioning

confidence: 69%

Section: Table 5 Correlation Between Dog1 Immunoexpression and Risk mentioning

confidence: 99%

Section: Table 5 Correlation Between Dog1 Immunoexpression and Risk mentioning

confidence: 99%

See 2 more Smart Citations

Histopathological Features of Gastrointestinal Stromal Tumors and the Contribution of DOG1 Expression to the Diagnosis

Guler¹,

Özyilmaz²,

Tokuç³

et al. 2015

Balkan Med J

View full text Add to dashboard Cite

show abstract

“…Protein kinase C-θ (PKC-θ) has been reported to be a useful biomarker for such tumors, as it is a downstream effector in the kit signaling pathway [24] [60]. DOG-1 (Discovered on GIST-1), also known as anoctamin 1, can assist in identifying some of these lesions as it holds a high specificity, possibly even higher than that of CD117, for the accurate diagnosis of GIST [8] [56] [60] [61]. Other tumors that may express DOG-1 include leiomyomas and certain GI carcinomas, especially squamous cell [56].…”

Section: Immunohistochemistrymentioning

confidence: 99%

Gastrointestinal Stromal Tumors in the 21<sup>st</sup> Century

Kanthan¹,

Senger²,

Ahmed³

et al. 2014

JCT

View full text Add to dashboard Cite

Gastrointestinal stromal tumours (GISTs) are rare mesenchymal lesions accounting for only 0.2% of all gastrointestinal neoplasms. These tumors arise from the interstitial cells of Cajal, with mutations described in proto-oncogenes such as KIT, PDGFRA, DOG-1, and SDH. The majority of these lesions are asymptomatic, thus the true incidence remains unknown. While patients typically undergo initial endoscopy, CT scan and/or MRI, findings are often nonspecific and require a biopsy to identify the tumor. As such, immunohistochemical evaluation is the gold-standard for the accurate diagnosis of GIST. Though surgical excision remains the gold-standard for curative management, the discovery of imatinib, a tyrosine kinase inhibitor (TKI), has revolutionized the treatment of GIST in the 21 st century as a "prototype" of molecular targeted therapy for solid tumors. Risk assessment for recurrence divides these tumors into low and high-risk categories. In the latter, a role for adjuvant therapy with TKI confers a significantly better prognosis than previously observed. However, secondary mutations conferring drug resistance remain an ongoing challenge for management, as few alternative treatment options are available for patients intolerant/refractory to TKI therapy. In this review, we summarize the epidemiology, molecular pathogenesis, clinical presentation, diagnosis, pathology features, management options, and prognostic features of GISTs.

show abstract

Subepithelial Lesions

Huang¹,

Saltzman²

2015

ERCP and EUS

View full text Add to dashboard Cite

Contribution of DOG1 expression to the diagnosis of gastrointestinal stromal tumors

Cited by 15 publications

References 40 publications

Histopathological Features of Gastrointestinal Stromal Tumors and the Contribution of DOG1 Expression to the Diagnosis

Histopathological Features of Gastrointestinal Stromal Tumors and the Contribution of DOG1 Expression to the Diagnosis

Gastrointestinal Stromal Tumors in the 21<sup>st</sup> Century

Subepithelial Lesions

Contact Info

Product

Resources

About

Contribution of DOG1 expression to the diagnosis of gastrointestinal stromal tumors

Cited by 15 publications

References 40 publications

Histopathological Features of Gastrointestinal Stromal Tumors and the Contribution of DOG1 Expression to the Diagnosis

Histopathological Features of Gastrointestinal Stromal Tumors and the Contribution of DOG1 Expression to the Diagnosis

Gastrointestinal Stromal Tumors in the 21&lt;sup&gt;st&lt;/sup&gt; Century

Subepithelial Lesions

Contact Info

Product

Resources

About

Gastrointestinal Stromal Tumors in the 21<sup>st</sup> Century